CRIS Current Research Information System

ROSELLINI, MATTEO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 2.229
NA - Nord America 867
EU - Europa 737
SA - Sud America 167
AF - Africa 94
Totale 4.094
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 846
SG - Singapore 832
CN - Cina 659
IT - Italia 230
VN - Vietnam 216
HK - Hong Kong 212
KR - Corea 166
BR - Brasile 128
NL - Olanda 126
DE - Germania 73
IN - India 70
SE - Svezia 66
CI - Costa d'Avorio 48
SC - Seychelles 35
FI - Finlandia 33
IE - Irlanda 33
GB - Regno Unito 29
RU - Federazione Russa 28
CH - Svizzera 25
FR - Francia 25
AT - Austria 20
JP - Giappone 19
JO - Giordania 17
AR - Argentina 15
ID - Indonesia 15
CA - Canada 14
BG - Bulgaria 13
CL - Cile 11
PL - Polonia 11
EC - Ecuador 6
BE - Belgio 5
LT - Lituania 5
PK - Pakistan 4
ZA - Sudafrica 4
BD - Bangladesh 3
CO - Colombia 3
ES - Italia 3
KZ - Kazakistan 3
MX - Messico 3
PT - Portogallo 3
TG - Togo 3
AE - Emirati Arabi Uniti 2
AL - Albania 2
DO - Repubblica Dominicana 2
TR - Turchia 2
UY - Uruguay 2
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
BY - Bielorussia 1
CY - Cipro 1
EE - Estonia 1
GR - Grecia 1
HN - Honduras 1
IL - Israele 1
IQ - Iraq 1
IR - Iran 1
KE - Kenya 1
KG - Kirghizistan 1
LB - Libano 1
LV - Lettonia 1
MA - Marocco 1
ML - Mali 1
MZ - Mozambico 1
NI - Nicaragua 1
PY - Paraguay 1
RS - Serbia 1
TH - Thailandia 1
UA - Ucraina 1
VE - Venezuela 1
Totale 4.094
Salva come PNG Salva come JPEG
Città #
Singapore 579
Hefei 295
Hong Kong 209
Ashburn 185
Seoul 165
Santa Clara 100
Beijing 79
Hanoi 62
Bologna 59
Ho Chi Minh City 55
Boardman 53
Abidjan 48
Chandler 40
Dublin 32
Los Angeles 32
Dallas 28
Bengaluru 27
Bern 22
Milan 22
Redondo Beach 22
Helsinki 21
Guangzhou 20
Tokyo 19
Amman 17
Castel Maggiore 17
Hyderabad 15
Buffalo 14
New York 14
Amsterdam 13
Munich 13
Nuremberg 13
Sofia 13
São Paulo 13
Vienna 13
Biên Hòa 12
Rome 12
Falkenstein 11
Shanghai 11
Tongling 11
Turin 11
Fairfield 10
Princeton 10
Lappeenranta 9
Southend 9
Frankfurt am Main 8
Jakarta 7
London 7
Montreal 7
Nanjing 7
Warsaw 7
Boston 6
Da Nang 6
Haiphong 6
Berlin 5
Brooklyn 5
Brussels 5
Chicago 5
Enschede 5
Hoofddorp 5
Houston 5
Moscow 5
Ninh Bình 5
Redmond 5
San Polo di Torrile 5
Zhengzhou 5
Bari 4
Boydton 4
Bühl 4
Changsha 4
Florence 4
Hải Dương 4
Phú Thọ 4
Quảng Ngãi 4
Rimini 4
Seattle 4
Toronto 4
Xi'an 4
Atlanta 3
Belo Horizonte 3
Bexley 3
Cambridge 3
Columbus 3
Ha Long 3
Lomé 3
Maipú 3
Mexico City 3
Modena 3
Mumbai 3
Paris 3
Phoenix 3
Quận Hai 3
Quận Một 3
Recife 3
Rio de Janeiro 3
San Diego 3
San Francisco 3
Santiago 3
Shijiazhuang 3
Sorocaba 3
Stockholm 3
Totale 2.673
Salva come PNG Salva come JPEG
Nome #
Insights into the impact of chromosome 3p mutations in advanced renal cell carcinoma treated with immune-based combinations or targeted therapy: A single-center experience 142
Bone targeting agents in patients with metastatic prostate cancer: State of the art 138
Immune checkpoint inhibitors in lung tumors with rare histologies and other thoracic malignancies 137
Bone Targeting Agents in Patients with Prostate Cancer: General Toxicities and Osteonecrosis of the Jaw 129
A hypothesis-generating analysis on the role of TERT promoter mutation in advanced urothelial carcinoma treated with immunotherapy 129
A prospective study on the early evaluation of response to androgen receptor-targeted agents with 11C-Choline, 68Ga-PSMA, and 18F-FACBC PET in metastatic castration-resistant prostate cancer: a single-center experience 127
Adjuvant PD-1 and PD-L1 Inhibitors and Relapse-Free Survival in Cancer Patients: The MOUSEION-04 Study 125
Prognostic Factors of Survival for High-Grade Neuroendocrine Neoplasia of the Bladder: A SEER Database Analysis 125
Tumor growth rate to assess therapy response to immune-based combinations for metastatic renal cell carcinoma 124
The value of molecular features in predicting efficacy of immuno-combinations in kidney cancer: just a drop in the ocean? 123
Dual-energy spectral CT in renal cell carcinoma: dawn of a brand-new era? 120
Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study 119
Hypertransaminasemia in metastatic renal cell carcinoma patients receiving immune-based combinations: a meta-analysis 112
Development and validation of a new tool to estimate early mortality in patients with advanced cancer treated with immunotherapy 110
State of the art of adjuvant immunotherapy in urothelial cancer: New developments and upcoming changes 107
Impact of HER2 assessment by CISH in urothelial carcinoma: A retrospective single-center experience 105
Novel Immune Checkpoint Inhibitor Targets in Advanced or Metastatic Renal Cell Carcinoma: State of the Art and Future Perspectives 101
Comparative effectiveness of first-line immune checkpoint inhibitors plus tyrosine kinase inhibitors according to IMDC risk groups in metastatic renal cell carcinoma: A meta-analysis 99
Chromosome 3p gene alterations as biomarkers for immunocombinations in metastatic renal cell carcinoma: A hypothesis-generating analysis 89
Quality of life assessment in renal cell carcinoma Phase II and III clinical trials published between 2010 and 2020: A systematic review 87
An update on safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma 81
The molecular characteristics of non‐clear cell renal cell carcinoma: What’s the story morning glory? 79
Immune-based combinations for the treatment of metastatic renal cell carcinoma: a meta-analysis of randomised clinical trials 77
Overall survival with adjuvant pembrolizumab in renal cell carcinoma — the shock of the lightning 75
Impact of Clinicopathological Features on Survival in Patients Treated with First-line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Meta-analysis of Randomized Clinical Trials 72
Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma 71
Treating prostate cancer by antibody-drug conjugates 67
Implications of TERT promoter mutations and telomerase activity in solid tumors with a focus on genitourinary cancers 65
The impact of ECOG performance status on efficacy of immunotherapy and immune-based combinations in cancer patients: the MOUSEION-06 study 64
Exploring the association between metastatic sites and androgen receptor splice variant 7 (AR-V7) in castration-resistant prostate cancer patients: A meta-analysis of prospective clinical trials 61
Hypertransaminasemia in cancer patients receiving immunotherapy and immune-based combinations: the MOUSEION-05 study 58
An insight on novel molecular pathways in metastatic prostate cancer: A focus on ddr, msi and akt 57
How Do Molecular Classifications Affect the Neoadjuvant Treatment of Muscle-Invasive Urothelial Carcinoma? 56
External validation of a red cell-based blood prognostic score in patients with metastatic renal cell carcinoma treated with first-line immunotherapy combinations 56
Treatment Options for Metastatic Urothelial Carcinoma After First-Line Chemotherapy 56
Adapting to hormone-therapy resistance for adopting the right therapeutic strategy in advanced prostate cancer 54
Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis 52
TERT promoter mutations and the outcome of patients with advanced urothelial carcinoma treated by platinum-based chemotherapy or pembrolizumab 51
Guiding treatment selection with immunotherapy compared to targeted therapy agents in patients with metastatic kidney cancer 50
Role of Hb to RDW ratio in metastatic renal cell carcinoma patients treated with first-line immunotherapy combinations 50
What is the risk of hepatotoxicity induced by immune-checkpoint inhibitors and how can we avoid it? 49
Do we need alternative PD-1 inhibitors for the treatment of renal cell carcinoma? 46
Current androgen receptor antagonists under investigation for resistant prostate cancer: progress and challenges 45
Current androgen receptor antagonists under investigation for resistant prostate cancer 44
Pembrolizumab plus lenvatinib or axitinib compared to nivolumab plus ipilimumab or cabozantinib in advanced renal cell carcinoma: a number needed to treat analysis 43
Concomitant Proton Pump Inhibitors and Outcome of Patients Treated with Nivolumab Alone or Plus Ipilimumab for Advanced Renal Cell Carcinoma 38
The Prognostic Role of 68GA-PSMA-PET/CT in Metastatic Hormone-Sensitive Prostate Cancer: A Preliminary Analysis 37
Prostate cancer and novel pharmacological treatment options - what's new for 2022? 36
Immune-based combinations for the treatment of metastatic renal cell carcinoma: a meta-analysis of randomised clinical trials 34
An up-to-date evaluation of cabozantinib for the treatment of renal cell carcinoma 32
Risk of toxicity with immunotherapy-tyrosine kinase inhibitors for metastatic renal cell carcinoma: a meta-analysis of randomized controlled trials 32
Re: Atezolizumab Plus Cabozantinib Versus Cabozantinib Monotherapy for Patients with Renal Cell Carcinoma After Progression with Previous Immune Checkpoint Inhibitor Treatment (CONTACT-03): A Multicentre, Randomised, Open-label, Phase 3 Trial 28
Determinants of treatment for first-line immune-based combinations in metastatic renal cell carcinoma: A critical overview of recent evidence 27
The impact of gender on The efficacy of immune checkpoint inhibitors in cancer patients: The MOUSEION-01 study 24
Peripheral neuropathy and headache in cancer patients treated with immunotherapy and immuno-oncology combinations: the MOUSEION-02 study 22
Sarcomatoid Differentiation in Renal Cell Carcinoma: Clinical and Pathologic Heterogeneity and Outcomes With Immune Checkpoint Inhibitors-Data From the ARON-1 Study 18
Immune-based Combinations in Intermediate-/Poor-risk Patients with Non-clear Cell Renal Cell Carcinoma: Results from the ARON-1 Study 18
Pathological and Clinical Implications of Tumor Microenvironment Evaluated With Multiplex Immunohistochemistry in Testicular Embryonal Carcinoma 15
Real-world evidences on adjuvant Pembrolizumab for renal cell carcinoma: results from the multicenter real-world ARON-1 study 14
Re: First-line Therapy for Advanced Non-Clear Cell Renal Cell Carcinoma. A Systematic Review and Meta-analysis 13
Totale 4.215
Salva come PNG Salva come JPEG
Categoria #
all - tutte 13.291
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 13.291
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202112 0 0 0 0 0 0 0 0 0 7 0 5
2021/202292 0 0 1 3 2 1 8 21 6 3 33 14
2022/2023365 5 15 7 17 36 35 21 19 95 11 55 49
2023/2024228 19 36 21 14 18 27 7 17 13 16 24 16
2024/20251.514 72 153 104 87 166 61 91 56 39 122 220 343
2025/20262.004 366 531 342 318 383 64 0 0 0 0 0 0
Totale 4.215